Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as brentuximab vedotin and Programmed Death-1 (PD-1) inhibitors. Although no randomized trials have been conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vassilakopoulos, Theodoros P., Asimakopoulos, John V., Konstantopoulos, Kostas, Angelopoulou, Maria K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026824/
https://www.ncbi.nlm.nih.gov/pubmed/32110285
http://dx.doi.org/10.1177/2040620720902911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026824/
https://www.ncbi.nlm.nih.gov/pubmed/32110285
http://dx.doi.org/10.1177/2040620720902911

Ejemplares similares